We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Beximco Pharma | LSE:BXP | London | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.00 | 2.74% | 37.50 | 36.00 | 39.00 | 37.50 | 37.00 | 37.00 | 1,080 | 08:33:50 |
TIDMBXP
RNS Number : 8937C
Beximco Pharmaceuticals Ltd
01 July 2016
BEXIMCO PHARMACEUTICALS LTD.
01 July, 2016
Payment of Cash Dividend
Beximco Pharmaceuticals Limited ("BPL", "Beximco Pharma" or "Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that the cash dividend of 10% of the nominal value per ordinary share/GDR (Taka 1 per ordinary share/GDR) for the year 2015, which was decided in the Board meeting held on 20(th) April, 2016, has been deposited with the custodian bank in Dhaka for onward credit to respective GDR holders' accounts.
For any queries regarding the credit of dividend to respective accounts of holders of GDRs, please contact the Depository (Bank of New York Mellon) representative, Mr. Vinu Kurian, at vinu.kurian@bnymellon.com.
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
Md. Asad Ullah, FCS, Executive Director & Company Secretary
Tel; +880 2 58611891, +880 2 58612040, Ext 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Sean Wyndham-Quin
Tel: +44 (0)20 3368 3551 / 3555
Daniel Stewart & Company plc (Broker)
Martin Lampshire
Tel: +44 (0)20 7776 6550
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,000 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Australia, Europe, Latin America and Canada among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including South Africa, Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria; Pacific Island; Latin and Central American countries; Middle East; Central Asia including Azerbaijan; South East Asia, including Singapore, Taiwan, Malaysia, Indonesia, Philippines and Hong Kong; Europe, including Austria, Germany and Romania and Australia.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DIVAKKDPABKDOAN
(END) Dow Jones Newswires
July 01, 2016 02:00 ET (06:00 GMT)
1 Year Beximco Pharma Chart |
1 Month Beximco Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions